[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

624.O2.6 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel Biologic Approaches to Indolent Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 7:00 AM-8:30 AM
Ballroom 20A (San Diego Convention Center)
Moderators:
Guillaume Cartron, MD, PhD, Hôpital Saint Eloi and Michael Millenson, MD, Fox Chase Cancer Center

Disclosures:
Cartron: GSK: Honoraria; Roche: Consultancy, Honoraria; LFB: Honoraria.
7:00 AM
Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Bertrand Coiffier, MD1*, Weimin Li2*, Erin D Henitz, BS2*, J. D. Karkera, PhD2*, Reyna Favis, PhD2*, Dana Gaffney, MS2*, Alice Shapiro, MS2*, Panteli Theocharous, BSc (hons), MSc, PhD3*, Yusri A Elsayed, MD, PhD2*, Helgi van de Velde, MD, PhD4*, Evgenii A Osmanov, MD, PhD5*, Xiaonan Hong, MD6*, Adriana Scheliga, MD7*, Fritz C. Offner, MD, PhD 8, Simon Rule9*, Adriana C Teixeira, MD10*, Jan Walewski, MD, PhD11, Sven de Vos, MD, PhD12, Michael Crump, MD, FRCPC13, Ofer Shpilberg, MD, MPH14*, Pier Luigi Zinzani, MD, PhD15, Andrew Z Cakana, MD, FRCPath3*, Dixie-Lee Esseltine, MD, FRCPC16, George Mulligan, PhD16* and Deborah S Ricci, PhD2*

1Departement d'Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite Cedex, France
2Janssen Research & Development, Raritan, NJ
3Janssen Research & Development, High Wycombe, United Kingdom
4Janssen Research & Development, Beerse, Belgium
5Cancer Research Center, Moscow, Russia
6Cancer Hospital, FuDan University, Shanghai, China
7INCA, Instituto Nacional De Cancer, Rio de Janeiro, Brazil
8Dienst Hematologie, University Hospital Ghent, Ghent, Belgium
9Department of Haematology, Derriford Hospital, Plymouth, United Kingdom
10Hospitais da Universidade de Coimbra, Coimbra, Portugal
11Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
12David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
13Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
14Institute of Hematology, Rabin Medical Center, Petah Tikva, Israel
15Department of Hematology and Oncology "Le A Seragnoli", Policlinico S.Orsola-Malpighi, Bologna, Italy
16Millennium Pharmaceuticals, Inc., Cambridge, MA

7:15 AM
Phase II Trial of Lenalidomide - Rituximab +/- Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

Tahamtan Ahmadi, MD, PhD1, Elise A. Chong, BA2*, Amanda Gordon, CRNP2*, Nicole A. Aqui, MD3*, YinYan Xu3*, Jakub Svoboda, MD2*, Sunita D. Nasta, MD2* and Stephen J. Schuster, MD2

1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
3Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

7:30 AM
Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment  (the IELSG#27 TRIAL)Clinically Relevant Abstract

Silvia Govi, MD1*, Riccardo Dolcetti, MD2*, Maurilio Ponzoni, MD3, Elisa Pasini, RF2*, Silvia Mappa, MD1*, Marta Bruno Ventre, MD1*, Claudio Doglioni, MD4*, Francesco Bertoni, MD5, Francesco Zaja, MD6*, Carlos Montalban, MD, PhD7, Caterina Stelitano, MD8*, Maria Elena Cabrera, MD9*, Franco Cavalli, MD10, Emanuele Zucca, MD11* and Andrés J.M. Ferreri, MD1*

1Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
2Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, Aviano, Italy
3Pathology Unit and Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
4Pathology Unit, Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
5Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
6Department of Experimental Medical and Clinical Sciences, Hematology, Udine, Italy
7Dept. of Int. Med., Hospital Ramon y Cajal, Madrid, Spain
8Dept. of Hematology, A.O. Malacrinò-Morelli, Reggio Calabria, Italy
9Dept. of Medicine, H Del Salvador, Santiago, Chile
10Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
11Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

7:45 AM
Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma: Results From a Phase I/II Study (BO20999)

Gilles Andre Salles1, Franck Morschhauser, MD, PhD2*, Catherine Thieblemont, MD3, Philippe Solal-Celigny4*, Thierry Lamy, MD, PhD5, Herve Tilly6, Pierre Feugier, MD, PhD7*, Steven Le Gouill, MD, PhD8*, Emmanuel Gyan, MD, PhD9,10*, Reda Bouabdallah, MD11, Michael K. Wenger, MD12, Elisabeth Wassner-Fritsch12*, Elina Asikanius12* and Guillaume Cartron, MD, PhD13*

1Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
2Centre Hospitalier Universitaire, Lille, France
3Hospital Saint-Louis, Paris, France
4Centre Jean Bernard, Clinique Victor Hugo, Le Mans, France
5Hematology Dept, CHU, Rennes, France
6Centre Henri Becquerel, Rouen, France
7Service d'Hématologie, Hôpital Adultes de Brabois, Vandoeuvre Les Nancy, France
8Hematology, CHU nantes, Nantes, France
9Service d'hématologie et thérapie cellulaire, CHRU de Tours, Tours, France
10Centre d'Investigations Cliniques, INSERM U202, CHRU de Tours, Tours, France
11Hematology Department, Lymphoma Program, Institut Paoli-Calmettes, Marseille, France
12F. Hoffmann-La Roche Ltd, Basel, Switzerland
13Service d'Hématologie-Oncologie Médicale, Hôpital Saint Eloi, Montpellier, France

8:00 AM
Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non‑Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Laurie H. Sehn, MD, MPH1, Andre Goy, MD2, Fritz C. Offner, MD, PhD 3, Giovanni Martinelli, MD4, Jonathan Friedberg, MD5, Susan F. Lasserre, MSc6*, Gregg Fine, MD7* and Oliver W. Press, MD, PhD8

1Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
2The John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
3Dienst Hematologie, University Hospital Ghent, Ghent, Belgium
4European Institute of Oncology, Milan, Italy
5James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
6Hoffman-La Roche Ltd., Basel, Switzerland
7Genentech, Inc., South San Francisco, CA
8Fred Hutchinson Cancer Research Center, Seattle, WA

8:15 AM
Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

John Radford, MD1*, Andrew Davies2*, Guillaume Cartron, MD, PhD3*, Franck Morschhauser, MD, PhD4*, Gilles Andre Salles5, Robert E. Marcus, MBBS, FRCP, FRCPath6, Michael K. Wenger7, Elina Asikanius7*, Elisabeth Wassner-Fritsch7* and Umberto Vitolo, MD8

1The Christie NHS Foundation Trust, Manchester, United Kingdom
2Cancer Sciences Division Somers Cancer Research Building, Southampton, United Kingdom
3Service d'Hématologie-Oncologie Médicale, Hôpital Saint Eloi, Montpellier, France
4Centre Hospitalier Universitaire, Lille, France
5Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
6Haematological Medicine, King's College Hospital, London, United Kingdom
7F. Hoffmann-La Roche Ltd, Basel, Switzerland
8Hematology, A.O. San Giovanni Battista, Torino, Italy

*signifies non-member of ASH